Janus Henderson Group
APGE icon

Janus Henderson Group’s Apogee Therapeutics APGE Stock Holding History

Janus Henderson Group’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$199M Buy
2,360,596
+297,992
+14% +$21.6M 0.09% 193
2025
Q4 		$156M Buy
2,062,604
+1,576,626
+324% +$99.3M 0.07% 221
2025
Q3 		$19.3M Sell
485,978
-23,343
-5% -$891K 0.01% 632
2025
Q2 		$22.1M Sell
509,321
-1,284,512
-72% -$48.9M 0.01% 546
2025
Q1 		$71.3M Buy
1,793,833
+658,733
+58% +$25.5M 0.04% 311
2024
Q4 		$51.5M Buy
1,135,100
+665,543
+142% +$33.9M 0.03% 384
2024
Q3 		$27.6M Buy
469,557
+458,157
+4,019% +$22M 0.01% 508
2024
Q2 		$449K Buy
11,400
+5,290
+87% +$257K ﹤0.01% 2044
2024
Q1 		$406K Sell
6,110
-473,576
-99% -$20.7M ﹤0.01% 2105
2023
Q4 		$13.4M Sell
479,686
-118,809
-20% -$2.38M 0.01% 621
2023
Q3 		$12.7M Buy
+598,495
New +$13.2M 0.01% 618

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Janus Henderson Group's APGE Position: Q1 2026 in Review

Janus Henderson Group increased its Apogee Therapeutics (APGE) stake by 14% in Q1 2026, buying an estimated $21.6M and bringing the position to 2,360,596 shares worth $199M. The position accounts for 0.09% of the portfolio, ranked #193.

Janus Henderson Group first reported a position in APGE in Q3 2023 and has held it in 11 quarters since. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Janus Henderson Group held 2,360,596 shares of Apogee Therapeutics worth $199M as of Q1 2026.
  • Janus Henderson Group bought 297,992 Apogee Therapeutics shares in Q1 2026, an estimated $21.6M.
  • Apogee Therapeutics made up 0.09% of Janus Henderson Group's portfolio in Q1 2026, its #193 holding.
  • Janus Henderson Group first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.